From www.bloodjournal.org by guest on June 17, 2017. For personal use only. insideblood 30 SEPTEMBER 2010 I VOLUME 116, NUMBER 13 ● ● ● CLINICAL TRIALS Comment on Wall et al, page 2241 You should see the other guy ---------------------------------------------------------------------------------------------------------------Morie A. Gertz MAYO CLINIC In this issue of Blood, Wall and colleagues report the use of radiolabeled 11-1F4 to visualize amyloid deposits.1 This biodistribution study in humans demonstrates the ability of an antibody to bind to and identify amyloid deposits in vivo. Typical amyloid palpebral purpura. iver uptake was seen in a high proportion of patients, although only 3 actually were felt to have clinically important hepatic amyloidosis. Unfortunately, 10 of the 18 patients with renal involvement and 3 of the 18 patients who had cardiac involvement without renal involvement had no uptake of the radiolabeled antibody in the kidney and heart, respectively. The fact that renal amyloid deposits in tissue sections (in vitro) immunostained weakly suggests that the antibody itself may not be able to bind to amyloid deposits in the kidney or heart and not because of antibody dosage. Despite these limitations, this report represents an exciting proof of principle. The imaging paper builds on previous research from this group L where human light-chain–associated tumors in mice underwent marked regression, without toxicity, after the administration of the same antibody.2 If there is to be any hope in improving the outcomes in patients with amyloidosis, there has to be a better mechanism for earlier detection of this disease. Not all patients will present with characteristic physical findings (see figure). Diagnostic physical findings of purpura or glossomegaly are found in only 15% of patients. Clinicians seek the availability of in vivo imaging that would specifically recognize amyloid for their patients, when the clinician suspects the diagnosis but is unwilling to en- blood 3 0 S E P T E M B E R 2 0 1 0 I V O L U M E 1 1 6 , N U M B E R 1 3 gage in a series of uncomfortable biopsies that entail a risk of bleeding. Attempts to improve on the diagnosis of cardiac amyloidosis using strain rate echocardiography3 as well as cardiac magnetic resonance imaging4 have recently been introduced in an attempt to identify cardiac amyloid deposits before significant functional compromise occurs. These are the patients most likely to benefit from chemotherapy or stem cell transplantation. The existence of a radio-immunoantibody capable of imaging amyloid deposits may prove to be of value in future monitoring of the disorder after therapy. Current techniques rely heavily on measurements of changes in the precursor protein, either the monoclonal protein in the serum or urine5 or the immunoglobulin-free light chain ratio in serum.6 Although these measures have been shown to correlate with outcomes, they do not directly assess what has happened with the actual amyloid deposits in the tissues. Imaging the amyloid burden at diagnosis, using the antibody, may have important prognostic value. This is reminiscent of the serum amyloid P (SAP) scan available in Europe, which can determine organ involvement and indicate the body amyloid load.7 SAP scintigraphy, which identifies all forms of amyloid deposits including hereditary and secondary forms, often reveals more widespread organ involvement than is identified clinically and represents useful additional information. Unfortunately, the SAP scan is not available in the United States, and investigators have had to rely on indirect evidence of organ involvement such as the serum alkaline phosphatase for liver amyloid, brain natriuretic peptide and troponin levels for cardiac amyloid, and the level of urinary protein loss for renal amyloid to assess organ involvement response and progression. The therapeutic potential of 11-1F4 cannot be overlooked. Once small tracer doses identify the deposits, investigation of the antibody’s ability to cause dissolution of the amyloid would be a natural next step. Similar 2199 From www.bloodjournal.org by guest on June 17, 2017. For personal use only. therapeutic approaches that involved depleting the SAP component have recently been published.8 Even if the current antibody does not bind to the heart or the liver, limited organ regression using an agent with a high therapeutic profile can set the stage for important immunotherapeutic approaches to the management of this devastating disease with successive generations of antiamyloid antibodies. Conflict-of-interest disclosure: The author declares no competing financial interests. ■ REFERENCES 1. Wall JS, Kennel SJ, Stuckey AC, et al. Radioimmunodetection of amyloid deposits in patients with AL amyloidosis. Blood. 2010;116(13):2241-2244. 2. Solomon A, Weiss DT, Wall JS. Therapeutic potential of chimeric amyloid-reactive monoclonal antibody 11-1F4. Clin Cancer Res. 2003;9(10 Pt 2):3831S-3838S. 3. Sun JP, Stewart WJ, Yang XS, et al. Differentiation of hypertrophic cardiomyopathy and cardiac amyloidosis from other causes of ventricular wall thickening by two-dimensional strain imaging echocardiography. Am J Cardiol. 2009; 103(3):411-415. 4. Syed IS, Glockner JF, Feng D, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging. 2010;3(2): 155-164. 5. Mollee P. Current trends in the diagnosis, therapy and monitoring of the monoclonal gammopathies. Clin Biochem Rev. 2009;30(3):93-103. 6. Pratt G. The evolving use of serum free light chain assays in haematology. Br J Haematol. 2008;141(4):413-422. 7. Hazenberg BP, van Rijswijk MH, Lub-de Hooge MN, et al. Diagnostic performance and prognostic value of extravascular retention of 123I-labeled serum amyloid P component in systemic amyloidosis. J Nucl Med. 2007;48(6): 865-872. 8. Gillmore JD, Tennent GA, Hutchinson WL, et al. Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. Br J Haematol. 2010;148(5):760-767. ● ● ● MYELOID NEOPLASIA Comment on Isakson et al, page 2324 A---------------------------------------------------------------------------------------------------------------new oncoprotein catabolism pathway Valérie Lallemand-Breitenbach and Hugues de Thé INSERM/CNRS/UNIVERSITÉ PARIS DIDEROT In this issue of Blood, Isakson et al identify autophagy as a new pathway for therapyinduced PML/RARA degradation, a critical determinant for leukemia eradication. Schematic representation of the 4 pathways implicated in PML/RARA degredation by retinoic acid or arsenic trioxide (see text for details). cute promyelocytic leukemia (APL) is characterized by the t(15;17) chromosomal translocation that fuses the promyelocytic leukemia (PML) gene with that of retinoic acid receptor A (RARA). This rare acute myeloid leukemia exhibits a differentiation block at the promyelocytic stage of granulo- A 2200 cytic maturation, hence its name. APL is a paradigm for oncoprotein-targeted therapy. Indeed, at the molecular level, the 2 clinically active therapies, all trans-retinoic acid (ATRA) and As2O3, both induce the degradation of the PML/RARA fusion protein. ATRA degrades both RARA and PML/ RARA, while conversely As2O3 degrades both PML and PML/RARA. Thus, these 2 serendipitously discovered agents actually target each of the 2 constitutive moieties of the oncoprotein (see figure). Several lines of evidence, among which is the synergistic effect of the ATRA/As2O3 combination for APL eradication in mice and man, have strongly implicated PML/RARA degradation in disease clearance.1-3 PML/RARA is a transcriptional repressor that binds both RARA response elements and de novo DNA sequences, resulting in dominant-negative and gain-of-function properties. Pharmacologic ATRA concentrations release PML/RARA-mediated transcriptional repression and induce differentiation. PML/RARA also disrupts structures formed by the normal PML protein, PML nuclear bodies. These enigmatic domains have been repeatedly implicated in control of cell death or self-renewal of normal or leukemia stem cells.4 Treatment-induced PML/RARA degradation reverses these effects, allowing differentiation and loss of clonogenic activity, as shown by transplantation studies in mice, culminating in APL eradication.2,3,5 Previous studies had identified 3 distinct pathways for therapy-induced PML/RARA degradation. The first one is cleavage of the PML moiety of PML/RARA by proteases activated by ATRA-induced differentiation.6 A second ATRA-initiated catabolic pathway activates direct proteasome-dependent degradation of DNA-bound, hormone-activated RARA or PML/RARA,7 a feedback mechanism conserved for all nuclear receptors. Finally, As2O3 targets the PML part of the fusion protein and specifically induces a SUMOdependent ubiquitin-mediated degradation process that was recently elucidated at the biochemical and cellular level.8 In the accompanying report,9 a fourth pathway, autophagy, was conclusively implicated in both ATRA- and As2O3-mediated PML/RARA degradation. The authors first demonstrate that PML/RARA is a highly insoluble protein. Misfolded proteins form aggregates that are often cleared by autophagy within the cytoplasm. The authors thus examine the consequence of activation or inhibition of autophagy on PML/RARA stability and observe that this process regulates basal PML/RARA protein levels. Importantly, both ATRA and As2O3 activate autophagy and 30 SEPTEMBER 2010 I VOLUME 116, NUMBER 13 blood From www.bloodjournal.org by guest on June 17, 2017. For personal use only. 2010 116: 2199-2200 doi:10.1182/blood-2010-06-289926 You should see the other guy Morie A. Gertz Updated information and services can be found at: http://www.bloodjournal.org/content/116/13/2199.full.html Articles on similar topics can be found in the following Blood collections Information about reproducing this article in parts or in its entirety may be found online at: http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests Information about ordering reprints may be found online at: http://www.bloodjournal.org/site/misc/rights.xhtml#reprints Information about subscriptions and ASH membership may be found online at: http://www.bloodjournal.org/site/subscriptions/index.xhtml Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society of Hematology, 2021 L St, NW, Suite 900, Washington DC 20036. Copyright 2011 by The American Society of Hematology; all rights reserved.
© Copyright 2026 Paperzz